Idarubicin: a brief overview on pharmacology and clinical use.
Peter Borchmann(University of Cologne), Andreas Engert(University Hospital Cologne), R. Schnell, Kai Hübel(University Hospital Cologne)
PubMed
February 1, 1997
Cited by 57
Related Papers
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist
|Blood|2003|717
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
|Journal of Clinical Oncology|2012|261
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
|Journal of Clinical Oncology|2017|248
Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation
|Journal of Clinical Oncology|2013|212